JSPR – jasper therapeutics, inc. - class a (US:NASDAQ)
Stock Stats
News
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $38.00 price target on the stock.
Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference [Yahoo! Finance]
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its price target lowered by analysts at HC Wainwright from $60.00 to $40.00. They now have a "buy" rating on the stock.
Form 4 Jasper Therapeutics, For: Feb 13 Filed by: MARTELL RON
Form 4 Jasper Therapeutics, For: Feb 13 Filed by: Mahal Jeetinder Singh
Form 4 Jasper Therapeutics, For: Feb 13 Filed by: Tucker Edwin Jonathan
Form 4 Jasper Therapeutics, For: Feb 13 Filed by: CROSS HERB
Form SCHEDULE 13G/A Jasper Therapeutics, Filed by: Soleus Capital Master Fund, L.P.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.